Lenalidomide-mediated enhanced translation of C/EBPα-p30 protein up-regulates expression of the antileukemic microRNA-181a in acute myeloid leukemia (Q36512601)

From Wikidata

Jump to navigation Jump to search

scientific article published on 25 October 2012

Language	Label	Description	Also known as
English	Lenalidomide-mediated enhanced translation of C/EBPα-p30 protein up-regulates expression of the antileukemic microRNA-181a in acute myeloid leukemia	scientific article published on 25 October 2012

Statements

scholarly article

1 reference

Europe PubMed Central

14 August 2017

Lenalidomide-mediated enhanced translation of C/EBPα-p30 protein up-regulates expression of the antileukemic microRNA-181a in acute myeloid leukemia (English)

1 reference

Europe PubMed Central

14 August 2017

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

acute myeloid leukemia

1 reference

based on heuristic

inferred from title

27

object named as

Guido Marcucci

1 reference

Europe PubMed Central

14 August 2017

Clara D. Bloomfield

25

object named as

Clara D Bloomfield

1 reference

Europe PubMed Central

14 August 2017

Krzysztof Mrózek

11

object named as

Krzysztof Mrózek

1 reference

Europe PubMed Central

14 August 2017

9

object named as

Kati Maharry

1 reference

Europe PubMed Central

14 August 2017

21

object named as

John C Byrd

1 reference

Europe PubMed Central

14 August 2017

Michael A Caligiuri

24

object named as

Michael A Caligiuri

1 reference

Europe PubMed Central

14 August 2017

Deedra Rae Nicolet

10

object named as

Deedra Nicolet

1 reference

Europe PubMed Central

14 August 2017

13

object named as

Anna M Eiring

1 reference

Europe PubMed Central

14 August 2017

26

object named as

Ramiro Garzon

1 reference

Europe PubMed Central

14 August 2017

22

object named as

William Blum

1 reference

Europe PubMed Central

14 August 2017

Sebastian Schwind

2

object named as

Sebastian Schwind

1 reference

Europe PubMed Central

14 August 2017

15

object named as

Heiko Becker

1 reference

Europe PubMed Central

14 August 2017

Ramasamy Santhanam

5

object named as

Ramasamy Santhanam

1 reference

Europe PubMed Central

14 August 2017

Christopher W Hickey

1

object named as

Christopher J Hickey

1 reference

Europe PubMed Central

14 August 2017

6

object named as

Anjali Mishra

1 reference

Europe PubMed Central

14 August 2017

Danilo Perrotti

16

object named as

Danilo Perrotti

1 reference

Europe PubMed Central

14 August 2017

20

object named as

Ravi Vij

1 reference

Europe PubMed Central

14 August 2017

Adrienne M Dorrance

4

object named as

Adrienne M Dorrance

1 reference

Europe PubMed Central

14 August 2017

8

object named as

Houda Alachkar

1 reference

Europe PubMed Central

14 August 2017

author name string

Hanna S Radomska

3

1 reference

Europe PubMed Central

14 August 2017

Yue-Zhong Wu

7

1 reference

Europe PubMed Central

14 August 2017

Alison Walker

12

1 reference

Europe PubMed Central

14 August 2017

Susan P Whitman

14

1 reference

Europe PubMed Central

14 August 2017

Lai-Chu Wu

17

1 reference

Europe PubMed Central

14 August 2017

Xi Zhao

18

1 reference

Europe PubMed Central

14 August 2017

Todd A Fehniger

19

1 reference

Europe PubMed Central

14 August 2017

L James Lee

23

1 reference

Europe PubMed Central

14 August 2017

language of work or name

0 references

publication date

25 October 2012

1 reference

Europe PubMed Central

14 August 2017

number of pages

11

1 reference

based on heuristic

inferred from page(s)

1 reference

Europe PubMed Central

14 August 2017

121

1 reference

Europe PubMed Central

14 August 2017

1

1 reference

Europe PubMed Central

14 August 2017

159-169

1 reference

Europe PubMed Central

14 August 2017

A phase 1/2 study of chemosensitization with the CXCR4 antagonist plerixafor in relapsed or refractory acute myeloid leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3538328

30 September 2017

Up-regulation of a HOXA-PBX3 homeobox-gene signature following down-regulation of miR-181 is associated with adverse prognosis in patients with cytogenetically abnormal AML.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3538328

30 September 2017

miR-181a sensitizes resistant leukaemia HL-60/Ara-C cells to Ara-C by inducing apoptosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3538328

30 September 2017

Nanochannel electroporation delivers precise amounts of biomolecules into living cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3538328

30 September 2017

miR-181 targets multiple Bcl-2 family members and influences apoptosis and mitochondrial function in astrocytes.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3538328

30 September 2017

Biochemical modulation of aracytidine (Ara-C) effects by GTI-2040, a ribonucleotide reductase inhibitor, in K562 human leukemia cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3538328

30 September 2017

miR-181a shows tumor suppressive effect against oral squamous cell carcinoma cells by downregulating K-ras

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3538328

30 September 2017

Prognostic significance of expression of a single microRNA, miR-181a, in cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3538328

30 September 2017

A phase 2 study of high-dose lenalidomide as initial therapy for older patients with acute myeloid leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3538328

30 September 2017

Dose escalation of lenalidomide in relapsed or refractory acute leukemias

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3538328

30 September 2017

Sp1/NFkappaB/HDAC/miR-29b regulatory network in KIT-driven myeloid leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3538328

30 September 2017

Elevated PIN1 expression by C/EBPalpha-p30 blocks C/EBPalpha-induced granulocytic differentiation through c-Jun in AML

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3538328

30 September 2017

miR-328 functions as an RNA decoy to modulate hnRNP E2 regulation of mRNA translation in leukemic blasts

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3538328

30 September 2017

Physiological and pathological roles for microRNAs in the immune system

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3538328

30 September 2017

Acute myeloid leukemia with biallelic CEBPA gene mutations and normal karyotype represents a distinct genetic entity associated with a favorable clinical outcome

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3538328

30 September 2017

Hematopoietic stem cell expansion precedes the generation of committed myeloid leukemia-initiating cells in C/EBPalpha mutant AML.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3538328

30 September 2017

Karyotype-specific microRNA signature in chronic lymphocytic leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3538328

30 September 2017

Complexity of CEBPA dysregulation in human acute myeloid leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3538328

30 September 2017

MicroRNAs in Cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3538328

30 September 2017

Double CEBPA mutations, but not single CEBPA mutations, define a subgroup of acute myeloid leukemia with a distinctive gene expression profile that is uniquely associated with a favorable outcome

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3538328

30 September 2017

Genome-wide epigenetic analysis delineates a biologically distinct immature acute leukemia with myeloid/T-lymphoid features.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3538328

30 September 2017

Prognostic significance of, and gene and microRNA expression signatures associated with, CEBPA mutations in cytogenetically normal acute myeloid leukemia with high-risk molecular features: a Cancer and Leukemia Group B Study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3538328

30 September 2017

hsa-mir-181a and hsa-mir-181b function as tumor suppressors in human glioma cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3538328

30 September 2017

MicroRNA expression in cytogenetically normal acute myeloid leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3538328

30 September 2017

Distinctive microRNA signature of acute myeloid leukemia bearing cytoplasmic mutated nucleophosmin

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3538328

30 September 2017

An erythroid differentiation signature predicts response to lenalidomide in myelodysplastic syndrome

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3538328

30 September 2017

Block of C/EBP alpha function by phosphorylation in acute myeloid leukemia with FLT3 activating mutations.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3538328

30 September 2017

Drug therapy for acute myeloid leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3538328

30 September 2017

Dephosphorylated C/EBPalpha accelerates cell proliferation through sequestering retinoblastoma protein

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3538328

30 September 2017

C/EBPalpha mutations in acute myeloid leukaemias

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3538328

30 September 2017

Phosphorylation of C/EBPalpha inhibits granulopoiesis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3538328

30 September 2017

Transcription activation function of C/EBPalpha is required for induction of granulocytic differentiation.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3538328

30 September 2017

Translational control of gene expression and disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3538328

30 September 2017

BCR-ABL suppresses C/EBPalpha expression through inhibitory action of hnRNP E2.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3538328

30 September 2017

C/EBPalpha arrests cell proliferation through direct inhibition of Cdk2 and Cdk4

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3538328

30 September 2017

Therapeutic options for acute myelogenous leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3538328

30 September 2017

Clinical importance of cytogenetics in acute myeloid leukaemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3538328

30 September 2017

Dominant-negative mutations of CEBPA, encoding CCAAT/enhancer binding protein-alpha (C/EBPalpha), in acute myeloid leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3538328

30 September 2017

Translational control of C/EBPalpha and C/EBPbeta isoform expression.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3538328

30 September 2017

C/EBPalpha inhibits cell growth via direct repression of E2F-DP-mediated transcription

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3538328

30 September 2017

A clonogenic common myeloid progenitor that gives rise to all myeloid lineages

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3538328

30 September 2017

CCAAT/enhancer binding protein alpha is a regulatory switch sufficient for induction of granulocytic development from bipotential myeloid progenitors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3538328

30 September 2017

Transcription factor C/EBPalpha: novel sites of expression and cloning of the human gene

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3538328

30 September 2017

Three levels of functional interaction determine the activity of CCAAT/enhancer binding protein-alpha on the serum albumin promoter

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3538328

28 June 2018

Target proteins of C/EBPalphap30 in AML: C/EBPalphap30 enhances sumoylation of C/EBPalphap42 via up-regulation of Ubc9.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3538328

21 September 2018

Biallelic mutations in the CEBPA gene and low CEBPA expression levels as prognostic markers in intermediate-risk AML.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3538328

21 September 2018

Mutations in the gene encoding the transcription factor CCAAT/enhancer binding protein alpha in myelodysplastic syndromes and acute myeloid leukemias

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3538328

21 September 2018

C/EBP proteins contain nuclear localization signals imbedded in their basic regions

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3538328

4 December 2018

Favorable prognostic significance of CEBPA mutations in patients with de novo acute myeloid leukemia: a study from the Acute Leukemia French Association (ALFA)

1 reference

https://pubmed.ncbi.nlm.nih.gov/23100311

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Prognostic impact, concurrent genetic mutations, and gene expression features of AML with CEBPA mutations in a cohort of 1182 cytogenetically normal AML patients: further evidence for CEBPA double mutant AML as a distinctive disease entity

1 reference

https://pubmed.ncbi.nlm.nih.gov/23100311

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1182/BLOOD-2012-05-428573

1 reference

Europe PubMed Central

14 August 2017

1 reference

Europe PubMed Central

14 August 2017

1 reference

Europe PubMed Central

14 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q36512601&oldid=1901878411"